NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma is nearing the completion of enrollment for its Phase 1b/2a clinical trial of ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, reported its financial and operational results for the third ...

Detailed price information for Nervgen Pharma Corp (NGENF) from The Globe and Mail including charting and trades.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated... "Lorem ipsum dolor sit amet, ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, after analysts at JPMorgan Chase & Co. predicted the Danish biotech ...

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dependency on compliance with FDA regulations for ...